ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-08: Form 8-K; Period of report 2012-11-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-11-01: Form 8-K; Period of report 2012-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-10-30: Form 8-K; Period of report 2012-10-30; Description 8.01 Other Events; Details 8.01.
- 2012-10-16: Form 8-K; Period of report 2012-10-16; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-08 | 8-K | 2012-11-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) and (e) On November 2, 2012, Dr. Thomas Chan, Chief Scientific Officer of ArQule, Inc. (“ArQule” or the “Registrant”) executed a separation agreement with ArQule under which his employment with ArQule will terminate on November 22, 2012. | t74956_8k.htm |
| 2012-11-01 | 8-K | 2012-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2012 ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter and nine months ended September 30, 2012. | t74890_8k.htm |
| 2012-10-30 | 8-K | 2012-10-30 | 8.01 Other Events | 8.01 ArQule, Inc. (“ArQule” or the “Registrant”) reports that Hakko Kirin Co., Ltd. (“Kyowa”), which has licensed from ArQule exclusive development rights to tivantinib in Japan and certain parts of Asia, has today issued a press release related to the discontinuation of its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial based on a recommendation by the trial’s Safety Review Committee. | t74882_8k.htm |
| 2012-10-16 | 8-K | 2012-10-16 | 8.01 Other Events | 8.01 On October 16, 2012, ArQule, Inc. (the “Registrant”) announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal Phase 3 trial of tivantinib in patients with hepatocellular carcinoma (HCC). | t74779_8k.htm |
| 2012-10-02 | 8-K | 2012-10-02 | 8.01 Other Events | 8.01 On October 2, 2012, ArQule, Inc. (the “Registrant”) and Daiichi Sankyo, Co., Ltd. (Daiichi Sankyo”) announced discontinuation of the Phase 3 MARQUEE pivotal trial of tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. | t74691_8k.htm |
| 2012-08-29 | 8-K | 2012-08-28 | 8.01 Other Events | 8.01 ArQule, Inc. (ArQule) has been informed by Kyowa Hakko Kirin Co., Ltd. (Kyowa), which has exclusive development rights to tivantinib in Japan and certain parts of Asia, of Kyowa’s decision to temporarily suspend patient enrollment in its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial. | t74482_8k.htm |
| 2012-08-02 | 8-K | 2012-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2012 ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2012. | t74267_8k.htm |
| 2012-06-04 | 8-K | 2012-06-02 | 7.01 Regulation FD Disclosure | 7.01 Regulation FD Disclosure.. | t73800_8k.htm |
| 2012-05-29 | 8-K | 2012-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | t73719_8k.htm | |
| 2012-05-18 | 8-K | 2012-05-18 | 8.01 Other Events | 8.01 On May 18, 2012, ArQule, Inc. (the “Registrant”) announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of its investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. | t73621_8k.htm |
| 2012-05-17 | 8-K | 2012-05-17 | 7.01 Regulation FD Disclosure | 7.01 On May 17, 2012, ArQule, Inc. (“ArQule” or the “Registrant”) issued a press release announcing clinical data from a recent randomized, controlled Phase 2 clinical trial of its drug candidate, tivantinib, as a single agent in previously treated patients with hepatocellular carcinoma (HCC). | t73607_8k.htm |
| 2012-05-03 | 8-K | 2012-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2012 ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2012. | t73412_8k.htm |
| 2012-04-12 | 8-K | 2012-04-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 —Entry into a Material Definitive Agreement. | t73146_8k.htm |
| 2012-04-10 | 8-K | 2012-04-10 | 8.01 Other Events | t73135_8k.htm | |
| 2012-03-01 | 8-K | 2012-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2012, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2011. | t72666_8k.htm |
| 2012-02-27 | 8-K/A | 2012-02-23 | 9.01 Financial Statements and Exhibits | 9.01 Exhibit No. 10.2 Amendment to Employment Agreement, dated February 23, 2012, by and between the Registrant and Brian Schwartz. | t72632_8ka.htm |
| 2012-02-24 | 8-K | 2012-02-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 23, 2012, the Compensation, Nominating and Governance Committee (the “Committee”) of ArQule, Inc. (the “Registrant”), approved an amendment to certain terms of the employment agreement, dated June 17, 2008, between the Registrant and Brian Schwartz, the Registrant’s Chief Medical Officer (the “Employment Agreement”). | t72613_8k.htm |
| 2012-01-17 | 8-K | 2012-01-17 | 8.01 Other Events | 8.01 On January 17, 2012, ArQule, Inc. (the “Registrant”) announced results of its Phase 2 clinical trial of the Registrant’s c-Met inhibitor, tivantinib, in patients with hepatocellular cancer. | t72344_8k.htm |